We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GlaxoSmithKline (GSK) Stock Moves -0.4%: What You Should Know
Read MoreHide Full Article
GlaxoSmithKline (GSK - Free Report) closed at $45.06 in the latest trading session, marking a -0.4% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.42%. At the same time, the Dow lost 0.49%, and the tech-heavy Nasdaq lost 0.47%.
Prior to today's trading, shares of the drug developer had gained 3.62% over the past month. This has outpaced the Medical sector's loss of 1.69% and the S&P 500's gain of 0.39% in that time.
GlaxoSmithKline will be looking to display strength as it nears its next earnings release. On that day, GlaxoSmithKline is projected to report earnings of $0.61 per share, which would represent a year-over-year decline of 1.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.22 billion, up 5.83% from the year-ago period.
Any recent changes to analyst estimates for GlaxoSmithKline should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.81% lower. GlaxoSmithKline is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, GlaxoSmithKline currently has a Forward P/E ratio of 14.04. This valuation marks a premium compared to its industry's average Forward P/E of 13.04.
Investors should also note that GSK has a PEG ratio of 3.01 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.01 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 210, which puts it in the bottom 18% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GSK in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GlaxoSmithKline (GSK) Stock Moves -0.4%: What You Should Know
GlaxoSmithKline (GSK - Free Report) closed at $45.06 in the latest trading session, marking a -0.4% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.42%. At the same time, the Dow lost 0.49%, and the tech-heavy Nasdaq lost 0.47%.
Prior to today's trading, shares of the drug developer had gained 3.62% over the past month. This has outpaced the Medical sector's loss of 1.69% and the S&P 500's gain of 0.39% in that time.
GlaxoSmithKline will be looking to display strength as it nears its next earnings release. On that day, GlaxoSmithKline is projected to report earnings of $0.61 per share, which would represent a year-over-year decline of 1.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.22 billion, up 5.83% from the year-ago period.
Any recent changes to analyst estimates for GlaxoSmithKline should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.81% lower. GlaxoSmithKline is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, GlaxoSmithKline currently has a Forward P/E ratio of 14.04. This valuation marks a premium compared to its industry's average Forward P/E of 13.04.
Investors should also note that GSK has a PEG ratio of 3.01 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.01 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 210, which puts it in the bottom 18% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GSK in the coming trading sessions, be sure to utilize Zacks.com.